Harbour Antibodies has received a double boost this week raising $3.3m (€2.5m) for its transgenic H2L2 mice technology and adding Pfizer to its list of clients.
The European Medicine’s Agency (EMA) has approved the first biosimilar monoclonal antibodies and expects to approve increasingly complex biosimilars as the regulatory framework becomes more flexible.
Merck Millipore hopes the promise of reducing the number of experiments needed during process development will win customers for its new MAb development kit.
Outsourcing-pharma.com presents a roundup of contract manufacturing news with deals for Lonza, DSM and Ark Therapeutics and an expanded agreement with Shire for AMRI.
GE Healthcare has launched an ‘off-the-shelf’ range of modular biomanufacturing facilities that it claims can be designed, constructed and operational in under two years.
Repligen should consider selling its bioprocessing unit, which sells materials used in mAb production, to make best use of its assets, a shareholder suggests.
Spectrum Pharmaceuticals and Viropro are to develop a biosimilar version of rituximab, a monoclonal antibody cancer treatment sold by Roche and Biogen Idec.
CMO Avid Bioservices’ revenues rose by 74 per cent to $2.1m (€1.5m) in Q2, generating a further $7m from its parent company, and it has plans to boost output and become a leader in mammalian cell culture production.
An increase in the sale of vaccines such as Quinvaxem and Epaxal, helped Dutch drugmaker Crucell reduce its loss some 56 per cent to €7.9m ($12.5m) in the second quarter.
According to a new report the therapeutic antibody market is
expected to treble in size by 2010 as significant leaps forward
coupled with safer and more effective humanised and fully human
antibodies are pouring onto the market fulfilling...
Integra Biosciences has launched the CELLine disposable flask,
which harnesses membrane technology that is suitable for
recombinant protein expression and high yield monoclonal antibody
production.
The European Commission has launched an €11.4 million project to
identify ways of improving the production of biologic drugs and
cutting the cost of treatment.
